Comparing DC subsets in solid tumors: what about DC3s?
Immunotherapy Advances · 30.12.2024 · 5 (1)
DOI: 10.1093/immadv/ltaf021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 30.05.2025. Verfasst von Casper J Pachocki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO.
Abstract (Originalsprache)
Dendritic cells (DCs) are critical sentinels of the immune system, serving as indispensable bridges between innate and adaptive immune responses. DCs are a heterogeneous population, with subsets playing specialized roles in immune defense, tolerance, or disease development. Among these, the recently redefined DC3 subset has gained attention for its unique features and potential roles in health and disease. This review focuses on the phenotypic, functional, and developmental diversity of DC subsets—primarily DC3s—and their contributions to cancer. The tumor microenvironment (TME) in solid tumors is characterized by varying degrees of immune cell infiltration, including DCs. Within the TME, DCs play diverse roles, either promoting anti-tumor responses or facilitating immune evasion. Key subsets include conventional type 1 and type 2 DCs (cDC1s and cDC2s), as well as plasmacytoid DCs (pDCs). DC3s share certain features with cDC2s and monocytes but are distinct in their phenotype, function, and ontogeny. Functionally, DC3s can prime and activate T cells, skewing CD4+ T cells towards Th17 and stimulating CD8+ T cells with a tissue-resident memory phenotype. In cancer, their presence correlates with diverse outcomes depending on the TME: DC3 presence is linked to increased survival in patients with pancreatic ductal adenocarcinoma and oropharyngeal cancer while in non-small-cell lung cancer and melanoma it is associated with immunosuppression. The emerging understanding of DC3s highlights the complexity of DC biology and its relevance to diseases. The dynamic immunomodulatory functions of DC3s open new avenues for developing targeted therapies against cancer and immune-mediated disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
- Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
- Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Biology and Immunology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
- Amsterdam Institute for Immunology and Infectious Diseases, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
ORCID-Profile: Casper J Pachocki, Marianne Boes, Alsya J Affandi
Förderung
- NWO
Zitieren
APA
Pachocki, C. J., Boes, M., & Affandi, A. J. (2024). Comparing DC subsets in solid tumors: what about DC3s?. Immunotherapy Advances, 5(1). https://doi.org/10.1093/immadv/ltaf021
Vancouver
Pachocki CJ, Boes M, Affandi AJ. Comparing DC subsets in solid tumors: what about DC3s?. Immunotherapy Advances. 2024;5(1). doi:10.1093/immadv/ltaf021
BibTeX
@article{Pachocki2024,
author = {Pachocki, Casper J and Boes, Marianne and Affandi, Alsya J},
title = {Comparing DC subsets in solid tumors: what about DC3s?},
journal = {Immunotherapy Advances},
year = {2024},
volume = {5},
number = {1},
doi = {10.1093/immadv/ltaf021}
}
EUVIMED